More exciting news:
Vilacto Bio Unveils Development Programs for LACTOACTIVE iTHER®
Press Release | 09/21/2018
COPENHAGEN, Denmark, Sept. 21, 2018 (GLOBE NEWSWIRE) — Vilacto Bio Inc. (OTC QB:VIBI) has revealed the initial five areas of development for its new LACTOACTIVE iTHER® compound.
LACTOACTIVE iTHER® is a new LACTOACTIVE variant that combines potent immune-system enhancement with a proven nanoparticle drug delivery system.
“Our own research suggests, and we firmly believe, that LACTOACTIVE iTHER® can contribute significantly to emerging therapies for treating a number of diseases, including cancer, immunodeficiency disorders, osteoarthritis, psoriasis, thrombocytopenia and others,” said
Vilacto Bio CEO Gert Anderson.
The areas where LACTOACTIVE iTHER® will be developed first include:
A bio-injection that could be useful in preventing metastasis of malignant tumor cells in cancer treatment due to the hydrocolloid potent (HA).
An inhaler spray to prevent recurrent upper respiratory tract infections (based on a 2016 study)
A vaccine injection for nanoparticle antibody source for a vaccine producer.
A new variant of gelatin capsules for patients with arthritis and other joint inflammation with fewer side effects – especially hypertension if people with diabetes – than Glucosamine.
Gums and candies and mouthwash, toothpaste for people with immune system deficiency, undergoing chemotherapy and suffering from oral inflammation.
These development programs are part of Vilacto Bio’s LACTOACTIVE iTHER® plan to form strategic partnerships with other biotech firms and become the “go-to” partner for enhancing new immunotherapy and vaccine solutions with its refined-colostrum compound “weaponized” as a nanomedicine.
AI
